Trade

Sanofi India share price

Moderate risk
  • 17%Low risk
  • 17%Moderate risk
  • 17%Balanced risk
  • 17%High risk
  • 17%Extreme risk
  • ₹4,061.00(0.13%)
    January 23, 2026 15:25:35 PM IST
    • NSE
    • BSE
  • Vol : 6.15 K (NSE + BSE)
    Last 20 day avg : 12.43 K

Sanofi India is trading 0.13% upper at Rs 4,061.00 as compared to its last closing price. Sanofi India has been trading in the price range of 4,085.00 & 4,055.70. Sanofi India has given -0.78% in this year & 0.84% in the last 5 days. Sanofi India has TTM P/E ratio 30.06 as compared to the sector P/E of 22.37.There are 3 analysts who have initiated coverage on Sanofi India. There are 1 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 76.00 Crores in its last quarter.Listed peers of Sanofi India include Sun Pharmaceutical Industries (-0.24%), Torrent Pharmaceuticals (-2.48%), Divi's Laboratories (-1.08%).The Mutual Fund holding in Sanofi India was at 9.46% in 31 Dec 2025. The MF holding has increased from the last quarter. The FII holding in Sanofi India was at 5.55% in 31 Dec 2025. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Jan 24, 2026, 05:08 PM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.84
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.02
    Lower than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    4.73
    Higher than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -0.85
    Indicates undervaluation
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
Price range
Day Range
Lowest
4,055.70
Highest
4,085.00
52 week range
Lowest
3,976.40
Highest
6,717.50
Sanofi India News
Sanofi India Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Sun Pharmaceutical Industries
Bearish
1,630.45-0.243,91,070.7236.245.770.920.50
Torrent Pharmaceuticals
Neutral
3,924.15-2.481,32,927.9567.3217.10.8317.62
Divi's Laboratories
Bearish
6,007.00-1.081,59,244.0878.6111.520.460.01
Dr Reddy's Laboratories
Neutral
1,235.151.481,03,084.5418.633.140.632.34
Cipla
Bearish
1,314.85-4.131,06,175.0422.953.870.870.81
Mutual Fund Ownership
View all
Baroda BNP Paribas Small Cap Fund Regular Growth
NA
  • Amount Invested (Cr.) 25.41
  • % of AUM 1.97
Nippon India Pharma Fund - Growth
NA
  • Amount Invested (Cr.) 142.60
  • % of AUM 1.71
PGIM India Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 1.80
  • % of AUM 1.65
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 11.95
  • % of AUM 1.47
Baroda BNP Paribas Mid Cap Fund Regular Plan Growth
3/5
  • Amount Invested (Cr.) 26.05
  • % of AUM 1.22
Sanofi India Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2025-10-29Quarterly Results & Interim Dividend
2025-07-31Quarterly Results
2025-05-14Quarterly Results
2025-02-27Audited Results & Final Dividend
2024-11-07Quarterly Results
About the company Sanofi India
  • IndustryBiotechnology & Drugs
  • ISININE058A01010
  • BSE Code500674
  • NSE CodeSANOFI
Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its product portfolio is focused on five therapeutic areas: diabetes, epilepsy, cardiology, allergy and pain care. In the diabetes area, the Company has an insulin portfolio under the brand name of Lantus, which helps in controlling high blood sugar in adults and children with diabetes mellitus. It also provides Toustar pen, along with dedicated Toujeo cartridges, addressing the need for a reusable delivery device. Combiflam, its product, helps to reduce pain and inflammation in conditions like headache, muscle and joint pain, and also reduces fever. Its brands also include Cardace, Allegra, Avil and Frisium. The Company has its own manufacturing facility in Goa. It has around 12 contract manufacturing organizations.
  • Management Info
  • Rachid AyariChief Financial Officer, Whole Time Director
  • Haresh ValaCompliance Officer, Company Secretary
  • Deepak AroraManaging Director, Additional Director
  • Mahadev GawadeWhole-Time Director and Site Director-Goa
  • Nitin AroraIndia Partnerships Lead
  • N. Suresh BabuSales & Customer Engagement Head - Diabetes
  • Bratin BagSenior Director - Ethics and Business Integrity, South Asia
  • Richa BakshiPeople Excellence Lead
  • Sudipta ChakrabortyHead of Legal, India
  • Arvind GadekarMedical Lead - International Pharma SE Asia & India
Sanofi India Share Price FAQs

Sanofi India is trading at 4061.00 as on Fri Jan 23 2026 09:55:35. This is 0.13% upper as compared to its previous closing price of 4055.60.

The market capitalization of Sanofi India is 9344.65 Cr as on Fri Jan 23 2026 09:55:35.

The average broker rating on Sanofi India is Buy. The breakup of analyst rating is given below -

  • 1 analysts have given a strong buy rating
  • 1 analysts have given a buy rating
  • 1 analysts have given a hold rating
  • 0.00 analysts have given a sell rating
  • 0.00 analysts have given a strong sell rating

The 52 wk high for Sanofi India is 6717.50 whereas the 52 wk low is 3976.40

Sanofi India can be analyzed on the following key metrics -

  • TTM P/E: 30.06
  • Sector P/E: 22.37
  • Dividend Yield: 4.73%
  • D/E ratio: -

Sanofi India reported a net profit of 413.30 Cr in 2024.

The Mutual Fund Shareholding was 9.46% at the end of 31 Dec 2025.

Quick Links
EQUITY QUICK LINKS
Sanofi India QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Business News/Market/Market Stats/  Sanofi India share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.